The classical follicular variant of follicle center lymphoma (FCL-fo) is associated with the chromosomal translocation t(14; 18)(q32;q21). However, the sole presence of this translocation is not sufficient for malignant transformation, as demonstrated by experiments in a transgenic mouse model. Most of the secondary changes, which play a central role in tumor development and progression and which are presumed to be of prognostic value, are gains and losses of chromosomal material. We analyzed 28 FCL-fo patients using comparative genomic hybridization (CGH). The most frequent imbalances were gains on chromosomes X, 7,8, 12, and 18 as well as losses of material on chromosome arm
B
ASED ON THE FIRST descriptions by N.E. Brill as "generalized giant lymph follicle hyperplasia of lymph nodes and spleen"' and by D. Symmers as "follicular lymphadenopathy with splenomegaly,"' the follicular variant of follicle center lymphoma (FCL-fo) is the type of nonHodgkin's lymphoma (NHL) recognized best. Ever since, this B-cell tumor has been given credit as a lymphoma entity in the most important lymphoma classification systems of the past and present such as the Kiel classification (centroblastid centrocytic, follicular), the Lukes/Collins classification (follicle center lymphoma, follicular), the Working Formulation (malignant lymphoma, follicular, small cleaved, and large cell), and the recently proposed list of lymphoid neoplasms3 (follicle center lymphoma, follicular) (for review see Warnke et aI4).
Apart from the characteristic histomorphology of follicle center lymphoma, the translocation t(14; 18)(q32;q21) was found to be a cytogenetic marker likewise typical of this neopla~m.~ At the molecular level, this translocation juxtaposes the BCL2 proto-oncogene located in band 18q21 to regulatory sequences of the Ig heavy-chain gene in band 14q32, resulting in enhanced BCL2 expression. Although BCL2 overexpression inhibits apoptosis, conferring a survival advantage to the t(14; 18)-positive cells,6' its sole presence does not render the cells malignant, as demonstrated in experiments with a transgenic mouse model.' Additional genetic alterations may occur in t( 14; 18)-immortalized cells finally causing the malignant transformation. These so-called secondary aberrations are of prognostic relevance in follicle center lymphoma. ' Although chromosomal banding analysis has been a useful and reliable tool for the identification of such secondary aberrations, this technique has important limitations in the analysis of lymphomas: (1) only metaphase cells can be analyzed and these cells may not be representative for the tumor cell clone in vivo'o*''; and (2) banding analysis depends on the availability of fresh tumor material. In most patients, this is obtained by lymph node biopsy at initial diagnosis. Because of logistical problems, in many instances a reliable transfer of fresh tumor tissue into the cytogenetic laboratory is not possible. Fluorescence in situ hybridization (FISH) using specific DNA probes allows the analysis of interphase cells in archival tissues. However, FISH depends on the preknowledge of candidate regions and on the availability of appropriate DNA probes. In addition, only a few regions of the genome can be analyzed within a FISH experiment (for review see Le Beau'' and Bentz et all3).
In contrast, the recently developed technique of comparative genomic hybridization (CGH)14 allows a rapid screening of chromosomal imbalances within tumor genomes. For CGH analysis, differentially labeled tumor and genomic control DNA are cohybridized to normal metaphase chromosomes under suppression conditions and detected via different fluorochromes. Digitized image analysis is used to measure the fluorescence intensities of tumor and control DNA and to calculate fluorescence ratio values for each chromosome region. Thus, overrepresented and underrepresented sequences can be identified within the tumor genome.14- 16 We used CGH to investigate chromosomal imbalances in tumor tissues of 28 patients with FCL-fo, the most frequent variant of follicle center lymphoma. ZgH-BCL2 fusion was present as demonstrated by polymerase chain reaction (in 16 patients, the breakpoint was located within the major breakpoint cluster region of the BCL2 gene and in 3 patients within the minor breakpoint cluster region). In the remaining 9 patients, no IgH-BCL2 fusion was detected.
Comparative genomic hybridization. Genomic DNA was prepared from tumor tissue as described" using proteinase K digestion and phenol-chloroform extraction. CGH was performed as reported previously."," Briefly, normal human genomic DNA (control DNA) was labeled with digoxigenin-l Ideoxyuridine triphosphate (dUTP; Boehringer Mannheim, Mannheim, Germany) and tumor DNA was labeled with biotin-16-dUTP (Boehringer Mannheim) by a standard nick translation reaction. One microgram of labeled tumor DNA, 1 y g of differentially labeled control DNA and 70 yg of human Cotl-DNA (BRL Life Sciences, Gaithersburg, MD) were cohybridized to slides with metaphase cells prepared from blood of a healthy donor. After hybridization for 2 to 3 days and posthybridization washes, control and test DNAs were detected via rhodamine and fluorescein isothiocyanate (FITC), respectively. Chromosomes were counterstained with 4,6-diamidino-2-phenylindole (DAPI), resulting in a Q banding-like pattern that was used for chromosome identification.
Digital image analysis. Image analysis was performed as described previously.'"~'" Images were acquired using an epifluorescence microscope (Axioplan Zeiss, Jena, Germany) equipped with a cooled CCD camera (Photometrics, Tucson, AZ). Ratio profiles of the fluorescence intensities of tumor-DNAs and control-DNAs were calculated for each individual chromosome using a dedicated software.*" For each patient, the mean ratio profiles of between 4 and 10 metaphase cells were computed. Ratio values of 1.25 and 0.75 were defined as upper and lower thresholds for the identification of chromosomal imbalances. These values have been used in several studies comparing CGH results with data obtained by other cytogenetic methods and have proven to provide robust criteria for the diagnosis of chromosomal gains and 10sses.l~~~' Overrepresentations were diagnosed as high-level amplifications when the fluorescence intensity values exceeded 2.0 or when the FITC fluorescence showed strong focal signals and the corresponding ratio profile was beyond the diagnostic threshold for overrepresentation. For the assignment of these high-level amplifications to chromosomal bands, the signal intensities were compared to the DAPI banding on individual chromosomes. The extension of other imbalanced regions was assessed by the comparison of the fluorescence ratio profiles with the corresponding regions in chromosome ideograms.
Inferphase cytogenetics. In 16 instances, imbalances identified by CGH were further analyzed using interphase cytogenetics. For these experiments, the following DNA probes were used: repetitive probes specific for the centromeric regions of chromosomes 7 (D7Z1), 12 (D1223), and X (DXZl, all obtained from Oncor Sciences, Gaithersburg, MD); "cos-pl6," a contig of eight cosmid clones covering 250 kb of the region containing the CDKN2 gene on chromosome 9~2 1 ,~' YAC probe 966b7 mapping to chromosome band 6q21 (kindly provided by P. Bray-Ward and D. Ward, Yale University, New Haven, CT) and cosmid probe cos-myc72 mapping to chromosome band 8q24 as well as cosmid probe IgH,' mapping to band 14q32." For hybridization, nuclei were isolated from frozen tissue samples as described. ' A 400-base pair MYC-specific probe (Oncogene Science, Uniondale, NY) was labeled by random priming using digoxigenin-1 1 -dUTP (Boehringer Mannheim). Hybridized sequences were detected via alkaline phosphatase conjugated to an antidigoxigenin-specific antibody (Boehringer Mannheim). For control hybridizations, the genomic fragment gMHC-I-D from the cardiac &myosin heavy-chain gene, MYH7, located on chromosome band 14q12-qI3, was used.*' The degree of MYC amplification was determined by densitometric measurements of the hybridization bands obtained with the two DNA probes.
RESULTS

Comparative genomic hybridization.
In 19 of the 28 patients, chromosomal gains or losses were identified by CGH analysis. An example of a hybridization experiment is shown in Fig 1A through C. Overrepresentations of chromosomal material were more frequent than underrepresentations (46 gains v 13 losses). The most frequent aberrations were gains on chromosomes X (7 patients), 7 (6 patients), 12 (5 patients), 8q (4 patients), and 18 (4 patients), as well as losses on the long arm of chromosome 6 (6 patients). A synopsis of all chromosomal imbalances is shown in Fig 2. High-level DNA amplifications were identified in 4 patients: nos. 7 (chromosomal band 8q24), 14 (bands 8q24 and 12q13), 16 (band 6p21), and 21 (band lp36). For each patient with high-level amplification, examples of the relevant chromosomes hybridized with the tumor DNA are shown in Fig ID. On each of the most frequently affected chromosomes, regional consensus areas were delineated by CGH analysis (see Figs 2 and 3) . On chromosome X, the whole chromosome was overrepresented in 4 patients, whereas in 3 patients (no. 7, 17, and 19) only the short arm was affected. One of the patients with aberrations of chromosome 7 had only a partial gain of this chromosome extending from 7pter to 7q2 1 (patient no. I 1 ). On chromosome 12, a high-level DNA amplification mapping to chromosome band 12q 13-q14 pinpointed a possible consensus region (patient no. 14). Similarly, 2 of the 4 patients with gains on chromosome 8q exhibited high-level amplifications of chromosomal band 8q24 (patients no. 7 and 14). On chromosome 18, the commonly overrepresented region mapped to bands 18q2 1 -q22 (defined by patients 2 and 16). For chromosome 6, two consensus regions of deletion were delineated on the long arm, one mapping to 6q13-ql6 (defined by patients no. 3 and 16) and one to 6q23-qter (defined by patients no. 6 and 14).
Interphase cytogenetics.
Based on the availability of sufficient material and suitable DNA probes, the CGH findings were tested using interphase cytogenetics. The results of these experiments are shown in Table I . In 9 patients (no. I , 3 , 4 , 7 , 8, 1 1, 16 , 17, and 27) chromosomal imbalances were identified by CGH and the results were confirmed by interphase cytogenetic analysis. In four instances, the ratio profiles exhibited a clear shift toward overrepresentation (chromosome 12 i n patient no. 4 mosomal region 14q21-qter in patient no. 13, and chromoAmpl$cation of the MYCprofo-oncogene. In one patient soma1 region 8q21-qter in patient no. 19) or toward under-(no. 7), a high-level DNA amplification mapping to chromorepresentation (chromosomal region 6q16-qter in patient some band 8q24 was identified. In another patient (no. 14), no. 17); however, the profiles did not exceed the diagnostic strong focal signals were seen at chromosomal band 8q24; cutoff values. In each of these patients, significant proporhowever, the ratio profile did not exceed the diagnostic tions of cells carrying the respective aberrations were threshold for overrepresentation (see Fig 1D) . This is the identified in the tumor samples (see Table l) .
band, where the MYC proto-oncogene is localized, that plays high-level DNA amplifications; grey symbols indicate cases in which the ratio profiles showed a clear shift toward underrepresentation or overrepresentation; however, the diagnostic thresholds were not reached. In these patients, the aberrations were subsequently confirmed by Southern blot hybridization (patient no. 14) and interphase cytogenetic analysis (patients no. 4, 13, 17, and 19; see also Table l ). The numbers on top of each line refer t o the patient analyzed.
a major role in the tumorigenesis of other types of NHL. To chain was hybridized to the same filters. The ratio of the test whether the MYC gene is amplified in patients no. 7 and MYC-and MYH-7-specific signals showed a sevenfold and 14, we performed Southern blot analysis of genomic DNA fourfold amplification of the MYC gene in patients no. 7 and from these tumors using the MYC-specific probe. For internal 14, respectively, proving that MYC is part of the amplicons standardization, a probe for the cardiac &myosin heavy in these patients.
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From Fig 3. Average ratio profiles of chromosomes X, 6, 8, 12, and 18 "Although the ratio profile did not exceed the diagnostic threshold for overrepresentation in this patient, a strong band-like hybridization signal was seen on chromosome 8 (see Fig 1D) . Southern blot hybridization revealed a fourfold amplification of the MYC proto-oncogene in patient 14. *In these patients, the ratio profiles were clearly shifted toward overrepresentation or underrepresentation. Interphase cytogenetic analysis showed underrepresentation of the terminal part of chromosome 6q and overrepresentation of chromosome 12 and the terminal part of chromosome 8 enh(lq,6p25q21,7,11q,l3q22q34,2lq2lq22) * In patient 7, the short arm of chromosome X was overrepresented. With an alphoid DNA probe mapping to centromere-specific sequences of this chromosome, one signal was seen in the majority of cells. This indicates that the centromere was not part of the overrepresented portion of chromosome X in this Datient. Using CGH, we identified numerous gains and losses, as well as five amplification sites in 28 patients with FCL-fo. The most frequent aberrations were gains on chromosomes X, 7, 8, 12 , and 18 as well as losses on the long arm of chromosome 6. In 11 patients, CGH findings were compared with data obtained by interphase cytogenetics. CGH findings were always confirmed, further substantiating the accuracy of our evaluation criteria.
Although these most frequent imbalances were identified before as recurrent secondary chromosome aberrations in t( 14; 18)-positive lyrnphoma~?~ for chromosomes X, 8, 12 , and 18, our CGH data allowed further narrowing of the relevant subregions. This was based on (1) comparison of the overrepresented regions resulting in delineation of the overlapping subregion (see Fig  2) , namely the short arm of chromosome X, and band q21-q22 of chromosome 18 containing the BCL2 and FVTl genes; or (2) the presence of a high-level DNA amplification on chromosomes 8 (band 8q24) and 12 (band 12ql3-ql4). Such commonly overrepresented regions can be used as entry points for the identification of genes relevant for tumor progression in patients carrying a specific secondary aberration.
In contrast to previous studies in NHL using other cytogenetic techniques, a high incidence of high-level DNA amplifications ( 5 amplified regions in 4 of the 28 patients) was identified. Using banding techniques, hallmarks for gene amplification (ie, double minute chromosomes or homogeneously staining regions) were identified only in 19 out of more than 3,000 cases of NHL."
The DNA amplifications of our series mapped to four different regions: lp36, 6~2 1 , 8q24 (2 patients), and 12q13-q14. Several candidate genes are located on these chromosomal bands, eg, the FGR protooncogene and CDC2L1, a tyrosine kinase interfering with the cell cycle on band lp36, proto-oncogenes NRASL3, PBX2, and PIMl on band 6p21 and MDM2 as well as proto-oncogenes ERBB3, GLI, and SAS on chromosomal band 12q13. '4 In 2 patients of this study, high-level DNA amplifications mapping to band 8q24 were present. This is the location of the MYC proto-oncogene. A synergy of activated MYC and BCL2 genes was demonstrated in double transgenic mice.35 These animals developed rapidly growing lymphomas with an immature phenotype. Therefore MYC was further analyzed in these patients using Southern blot analysis. In both patients, amplification of the MYC gene was present. In a previous study, amplification of this gene in a patient with a chronic B-cell leukemia" was demonstrated. These data suggest that activation of MYC via a gene amplification is not a rare event in low-grade lymphoproliferative disorders.
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From To date, two other studies investigating a series of patients with lymphoproliferative disorders by CGH have been publ i~h e d . " .~~ Similar to the study in FCL-fo, in both series, high-level DNA amplifications were identified. Taken together, such amplifications were found in 12 instances in a total of 82 patients. In addition to the high sensitivity with respect to the detection of gene amplifications, CGH points to the chromosomal localization of the amplified sequences. This provides important information for the identification of the relevant genes involved in the amplification unit. For 5 of the 12 high-level DNA amplifications, involvement of specific proto-oncogenes in the amplification unit could be shown, In another study based on CGH data of a patient with diffuse large cell lymphoma, a high incidence of REL gene amplifications was identified in this type of lymphoma.37 Thus, gene amplifications appear to be much more important for tumor progression than previously assumed both in high-grade and low-grade NHL.
